{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:04Z","timestamp":1787003644788,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074425"],"award-info":[{"award-number":["82074425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06617-2","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:09:18Z","timestamp":1751414958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050"],"prefix":"10.1038","volume":"15","author":[{"given":"Jincheng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuomei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puhua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"6617_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598\u20131606 (2022).","journal-title":"J. Hepatol."},{"key":"6617_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","volume":"17","author":"Z Wu","year":"2024","unstructured":"Wu, Z., Xia, F. & Lin, R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021. J. Hematol. Oncol. 17, 119 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"6617_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in china, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"6617_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cac2.12393","volume":"43","author":"R Feng","year":"2023","unstructured":"Feng, R. et al. Cancer situation in china: what does the China cancer map indicate from the first National death survey to the latest cancer registration? Cancer Commun. (Lond). 43, 75\u201386 (2023).","journal-title":"Cancer Commun. (Lond)"},{"key":"6617_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL). European association for the study of diabetes (EASD), & European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"6617_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"6617_CR7","doi-asserted-by":"publisher","first-page":"e0629","DOI":"10.1097\/HC9.0000000000000629","volume":"9","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul, P. et al. Increased MASH-associated liver cancer in younger demographics. Hepatol. Commun. 9, e0629 (2025).","journal-title":"Hepatol. Commun."},{"key":"6617_CR8","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0043","author":"S Shiina","year":"2025","unstructured":"Shiina, S. et al. Liver disease trends in the Asia-Pacific region for the next 50 years. Clin. Mol. Hepatol. https:\/\/doi.org\/10.3350\/cmh.2025.0043 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"6617_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","volume":"34","author":"DQ Huang","year":"2022","unstructured":"Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell. Metab. 34, 969\u2013977e2 (2022).","journal-title":"Cell. Metab."},{"key":"6617_CR10","doi-asserted-by":"publisher","first-page":"100723","DOI":"10.1016\/j.xcrm.2022.100723","volume":"3","author":"A Craciun","year":"2022","unstructured":"Craciun, A. & Cortez-Pinto, H. Alarming increase of NASH as cause of liver cancer. Cell. Rep. Med. 3, 100723 (2022).","journal-title":"Cell. Rep. Med."},{"key":"6617_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hep.32758","volume":"77","author":"DJH Tan","year":"2023","unstructured":"Tan, D. J. H. et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology 77, 1150\u20131163 (2023).","journal-title":"Hepatology"},{"key":"6617_CR12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.34172\/ija.2023.e5","volume":"1","author":"M Noori","year":"2023","unstructured":"Noori, M. et al. The burden of cancers and their attributable risk factors among Iranian adults aged 70 and above, 1990\u20132019. Int. J. Aging. 1, e5\u2013e5 (2023).","journal-title":"Int. J. Aging"},{"key":"6617_CR13","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.34172\/ija.2023.e16","volume":"1","author":"S Safiri","year":"2023","unstructured":"Safiri, S., Asghari, K. M. & Sullman, M. J. M. The global burden of diseases and injuries among older adults. Int. J. Aging. 1, e16\u2013e16 (2023).","journal-title":"Int. J. Aging"},{"key":"6617_CR14","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Comparative analysis of cancer statistics in China and the united States in 2024. Chin. Med. J. (Engl). 137, 3093\u20133100 (2024).","journal-title":"Chin. Med. J. (Engl)"},{"key":"6617_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s00535-023-02040-4","volume":"58","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Global, regional, and National burden of liver cancer due to non-alcoholic steatohepatitis, 1990\u20132019: a decomposition and age-period-cohort analysis. J. Gastroenterol. 58, 1222\u20131236 (2023).","journal-title":"J. Gastroenterol."},{"key":"6617_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet 403, 2133\u20132161 (2024).","journal-title":"Lancet"},{"key":"6617_CR17","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet 403, 2100\u20132132 (2024).","journal-title":"Lancet"},{"key":"6617_CR18","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBD 2021 Risk Factors Collaborators","year":"2024","unstructured":"GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet 403, 2162\u20132203 (2024).","journal-title":"Lancet"},{"key":"6617_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"GBD 2021 Demographics Collaborators","year":"2024","unstructured":"GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of disease study 2021. Lancet 403, 1989\u20132056 (2024).","journal-title":"Lancet"},{"key":"6617_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and National burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"6617_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of disease study 2019. Lancet 400, 563\u2013591 (2022).","journal-title":"Lancet"},{"key":"6617_CR22","doi-asserted-by":"publisher","first-page":"04142","DOI":"10.7189\/jogh.14.04142","volume":"14","author":"M Yuan","year":"2024","unstructured":"Yuan, M. et al. Global burden and attributable risk factors of breast cancer in young women: historical trends from 1990 to 2019 and forecasts to 2030 by sociodemographic index regions and countries. J. Glob Health. 14, 04142 (2024).","journal-title":"J. Glob Health"},{"key":"6617_CR23","doi-asserted-by":"publisher","first-page":"116705","DOI":"10.1016\/j.ecoenv.2024.116705","volume":"282","author":"Z Ghaemi","year":"2024","unstructured":"Ghaemi, Z. & Noshadi, M. Evaluation of fluoride exposure using disability-adjusted life years and health risk assessment in south-western iran: A novel Monte Carlo simulation. Ecotoxicol. Environ. Saf. 282, 116705 (2024).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"6617_CR24","doi-asserted-by":"publisher","first-page":"103450","DOI":"10.1016\/j.autrev.2023.103450","volume":"22","author":"F Cao","year":"2023","unstructured":"Cao, F. et al. Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019. Autoimmun. Rev. 22, 103450 (2023).","journal-title":"Autoimmun. Rev."},{"key":"6617_CR25","first-page":"46","volume":"11","author":"B Lv","year":"2024","unstructured":"Lv, B. et al. Epidemiological trends of subarachnoid hemorrhage at global, regional, and National level: a trend analysis study from 1990 to 2021. Mil Med. Res. 11, 46 (2024).","journal-title":"Mil Med. Res."},{"key":"6617_CR26","doi-asserted-by":"publisher","first-page":"135319","DOI":"10.1016\/j.jhazmat.2024.135319","volume":"477","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Global, regional, and National burden of cancers attributable to particulate matter pollution from 1990 to 2019 and projection to 2050: worsening or improving? J. Hazard. Mater. 477, 135319 (2024).","journal-title":"J. Hazard. Mater."},{"key":"6617_CR27","doi-asserted-by":"publisher","first-page":"e2300078","DOI":"10.1002\/bimj.202300078","volume":"65","author":"E Skarstein","year":"2023","unstructured":"Skarstein, E., Martino, S. & Muff, S. A joint bayesian framework for missing data and measurement error using integrated nested Laplace approximations. Biom J. 65, e2300078 (2023).","journal-title":"Biom J."},{"key":"6617_CR28","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism 160, 155999 (2024).","journal-title":"Metabolism"},{"key":"6617_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in china: a cross-sectional comparative study. BMC Gastroenterol. 21, 212 (2021).","journal-title":"BMC Gastroenterol."},{"key":"6617_CR30","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s11427-021-2079-7","volume":"65","author":"B Zhang","year":"2022","unstructured":"Zhang, B. et al. Expert consensus on organizing the multidisciplinary team (MDT) diagnosis and treatment of hepato-pancreato-biliary diseases in China. Sci. China Life Sci. 65, 1036\u20131039 (2022).","journal-title":"Sci. China Life Sci."},{"key":"6617_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","volume":"29","author":"M Pinter","year":"2023","unstructured":"Pinter, M., Pinato, D. J., Ramadori, P. & Heikenwalder, M. NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin. Cancer Res. 29, 513\u2013520 (2023).","journal-title":"Clin. Cancer Res."},{"key":"6617_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","volume":"79","author":"N Yahoo","year":"2023","unstructured":"Yahoo, N., Dudek, M., Knolle, P. & Heikenw\u00e4lder, M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J. Hepatol. 79, 538\u2013551 (2023).","journal-title":"J. Hepatol."},{"key":"6617_CR33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie, J. et al. CXCR2 Inhibition enables NASH-HCC immunotherapy. Gut 71, 2093\u20132106 (2022).","journal-title":"Gut"},{"key":"6617_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","volume":"34","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell. Metab. 34, 1359\u20131376e7 (2022).","journal-title":"Cell. Metab."},{"key":"6617_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01251-0","volume":"7","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct. Target. Ther. 7, 1\u201340 (2022).","journal-title":"Sig Transduct. Target. Ther."},{"key":"6617_CR36","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1038\/s41467-024-53236-y","volume":"15","author":"X Cao","year":"2024","unstructured":"Cao, X. et al. Disparities in high fasting plasma glucose-related cardiovascular disease burden in China. Nat. Commun. 15, 8817 (2024).","journal-title":"Nat. Commun."},{"key":"6617_CR37","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.jnha.2024.100261","volume":"28","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019. J. Nutr. Health Aging. 28, 100261 (2024).","journal-title":"J. Nutr. Health Aging"},{"key":"6617_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","volume":"36","author":"S Gallage","year":"2024","unstructured":"Gallage, S. et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1. Cell. Metab. 36, 1371\u20131393e7 (2024).","journal-title":"Cell. Metab."},{"key":"6617_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2023.10.018","volume":"80","author":"J Padilla","year":"2024","unstructured":"Padilla, J. et al. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model. J. Hepatol. 80, 282\u2013292 (2024).","journal-title":"J. Hepatol."},{"key":"6617_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562\u2013568 (2022).","journal-title":"Nature"},{"key":"6617_CR41","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/antiox13121532","volume":"13","author":"I Mignini","year":"2024","unstructured":"Mignini, I. et al. Interplay of oxidative stress, gut microbiota, and nicotine in Metabolic-Associated steatotic liver disease (MASLD). Antioxid. (Basel). 13, 1532 (2024).","journal-title":"Antioxid. (Basel)"},{"key":"6617_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000735","author":"S Driessen","year":"2023","unstructured":"Driessen, S. et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000735 (2023).","journal-title":"Hepatology"},{"key":"6617_CR43","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/thorax-2024-222391","volume":"80","author":"C Plum","year":"2025","unstructured":"Plum, C. et al. Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study. Thorax 80, 248\u2013250 (2025).","journal-title":"Thorax"},{"key":"6617_CR44","doi-asserted-by":"publisher","first-page":"821384","DOI":"10.3389\/fpubh.2022.821384","volume":"10","author":"J Jiang","year":"2022","unstructured":"Jiang, J., Huang, W., Liu, Y. & Wang, Z. The Temporal and Spatial changes of health inequality in rural China. Front. Public. Health. 10, 821384 (2022).","journal-title":"Front. Public. Health"},{"key":"6617_CR45","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1016\/S2468-2667(23)00242-6","volume":"8","author":"KH Chan","year":"2023","unstructured":"Chan, K. H., Xiao, D., Zhou, M., Peto, R. & Chen, Z. Tobacco control in China. Lancet Public. Health. 8, e1006\u2013e1015 (2023).","journal-title":"Lancet Public. Health"},{"key":"6617_CR46","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan, K. E. et al. Global prevalence and clinical characteristics of Metabolic-associated fatty liver disease: A Meta-Analysis and systematic review of 10 739 607 individuals. J. Clin. Endocrinol. Metab. 107, 2691\u20132700 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6617_CR47","doi-asserted-by":"publisher","first-page":"156015","DOI":"10.1016\/j.metabol.2024.156015","volume":"161","author":"T Lan","year":"2024","unstructured":"Lan, T. & Tacke, F. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies. Metabolism 161, 156015 (2024).","journal-title":"Metabolism"},{"key":"6617_CR48","doi-asserted-by":"publisher","first-page":"107971","DOI":"10.1016\/j.ypmed.2024.107971","volume":"184","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults. Prev. Med. 184, 107971 (2024).","journal-title":"Prev. Med."},{"key":"6617_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(21)00047-4","volume":"9","author":"Q Zeng","year":"2021","unstructured":"Zeng, Q., Li, N., Pan, X. F., Chen, L. & Pan, A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 9, 393\u2013405 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"6617_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362\u2013373 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"6617_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","volume":"165","author":"S Man","year":"2023","unstructured":"Man, S. et al. Prevalence of liver steatosis and fibrosis in the general population and various High-Risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology 165, 1025\u20131040 (2023).","journal-title":"Gastroenterology"},{"key":"6617_CR52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41430-020-00765-6","volume":"75","author":"C Gao","year":"2021","unstructured":"Gao, C., Xu, J., Liu, Y. & Yang, Y. Nutrition policy and healthy China 2030 Building. Eur. J. Clin. Nutr. 75, 238\u2013246 (2021).","journal-title":"Eur. J. Clin. Nutr."},{"key":"6617_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S2213-8587(21)00118-2","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Zhao, L., Gao, L., Pan, A. & Xue, H. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol. 9, 446\u2013461 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"6617_CR54","doi-asserted-by":"publisher","first-page":"216334","DOI":"10.1016\/j.canlet.2023.216334","volume":"574","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. The past, present, and future of liver cancer research in China. Cancer Lett. 574, 216334 (2023).","journal-title":"Cancer Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06617-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:15:24Z","timestamp":1751422524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06617-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23255"}}